CN100562521C - 作为酪蛋白激酶Iε抑制剂的被取代的噻吩并吡咯甲酸酰胺、吡咯并噻唑甲酸酰胺以及相关类似物 - Google Patents
作为酪蛋白激酶Iε抑制剂的被取代的噻吩并吡咯甲酸酰胺、吡咯并噻唑甲酸酰胺以及相关类似物 Download PDFInfo
- Publication number
- CN100562521C CN100562521C CNB2005800269958A CN200580026995A CN100562521C CN 100562521 C CN100562521 C CN 100562521C CN B2005800269958 A CNB2005800269958 A CN B2005800269958A CN 200580026995 A CN200580026995 A CN 200580026995A CN 100562521 C CN100562521 C CN 100562521C
- Authority
- CN
- China
- Prior art keywords
- acid amides
- benzoic acid
- pyrroles
- alkyl
- thieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60334704P | 2004-08-19 | 2004-08-19 | |
| US60/603,347 | 2004-08-19 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101001861A CN101001861A (zh) | 2007-07-18 |
| CN100562521C true CN100562521C (zh) | 2009-11-25 |
Family
ID=35695546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005800269958A Expired - Fee Related CN100562521C (zh) | 2004-08-19 | 2005-08-18 | 作为酪蛋白激酶Iε抑制剂的被取代的噻吩并吡咯甲酸酰胺、吡咯并噻唑甲酸酰胺以及相关类似物 |
Country Status (30)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548212A (en) | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
| US8053603B2 (en) | 2006-01-06 | 2011-11-08 | Sunovion Pharmaceuticals Inc. | Tetralone-based monoamine reuptake inhibitors |
| KR101294014B1 (ko) | 2006-01-06 | 2013-08-09 | 선오비온 파마슈티컬스 인코포레이티드 | 모노아민 재흡수 저해제로서의 시클로알킬아민 |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| EP1955699A1 (en) * | 2007-02-08 | 2008-08-13 | Boehringer Ingelheim Pharma GmbH & Co. KG | Use of flibanserin for the treatment of insomnia |
| MX2009012685A (es) | 2007-05-31 | 2009-12-14 | Sepracor Inc | Cicloalquilaminas sustituidas con fenilo como inhibidores de la reabsorcion de monoamina. |
| JP4748823B2 (ja) * | 2009-02-12 | 2011-08-17 | 株式会社ファルマデザイン | カゼインキナーゼ1δ及びカゼインキナーゼ1ε阻害剤 |
| UA106082C2 (uk) * | 2009-05-28 | 2014-07-25 | Вертекс Фармасьютікалз Інкорпорейтед | АМІНОПІРАЗОЛ ТРИАЗОЛОТІАДІАЗОЛЬНІ ІНГІБІТОРИ ПРОТЕЇНКІНАЗИ c-МЕТ |
| MX2012004997A (es) * | 2009-10-28 | 2012-06-12 | Pfizer | Derivados de imidazol como inhibidores de la caseina quinasa. |
| DE102009058280A1 (de) * | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | Thiazolderivate |
| CN104803997A (zh) * | 2010-08-09 | 2015-07-29 | 株式会社创药分子设计 | 酪蛋白激酶1δ及酪蛋白激酶1ε抑制剂 |
| CN109748927A (zh) * | 2017-11-03 | 2019-05-14 | 上海交通大学医学院附属瑞金医院 | 杂芳基酰胺类化合物、其制备方法、药用组合物及其应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555328B1 (en) * | 1999-06-08 | 2003-04-29 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythms and for human casein kinase I δ and/or ε phosphorylation of human clock proteins, period 1, -2 and -3 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
| CN100439367C (zh) * | 2003-12-11 | 2008-12-03 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物 |
-
2005
- 2005-07-18 JO JO2005104A patent/JO2629B1/en active
- 2005-08-09 GT GT200500215A patent/GT200500215A/es unknown
- 2005-08-09 SV SV2005002190A patent/SV2006002190A/es not_active Application Discontinuation
- 2005-08-16 AR ARP050103439A patent/AR051008A1/es unknown
- 2005-08-17 PE PE2005000956A patent/PE20060630A1/es not_active Application Discontinuation
- 2005-08-18 CN CNB2005800269958A patent/CN100562521C/zh not_active Expired - Fee Related
- 2005-08-18 PT PT05826812T patent/PT1784409E/pt unknown
- 2005-08-18 JP JP2007528007A patent/JP4869232B2/ja not_active Expired - Fee Related
- 2005-08-18 BR BRPI0514419-1A patent/BRPI0514419A/pt not_active Application Discontinuation
- 2005-08-18 CA CA2577879A patent/CA2577879C/en not_active Expired - Fee Related
- 2005-08-18 WO PCT/US2005/029383 patent/WO2006021000A2/en not_active Ceased
- 2005-08-18 RS RSP-2010/0401A patent/RS51413B/sr unknown
- 2005-08-18 SI SI200531094T patent/SI1784409T1/sl unknown
- 2005-08-18 PL PL05826812T patent/PL1784409T3/pl unknown
- 2005-08-18 EP EP05826812A patent/EP1784409B1/en not_active Expired - Lifetime
- 2005-08-18 DK DK05826812.9T patent/DK1784409T3/da active
- 2005-08-18 AU AU2005272584A patent/AU2005272584B2/en not_active Ceased
- 2005-08-18 HR HR20100475T patent/HRP20100475T1/hr unknown
- 2005-08-18 KR KR1020077003865A patent/KR20070045263A/ko not_active Abandoned
- 2005-08-18 AT AT05826812T patent/ATE471326T1/de active
- 2005-08-18 RU RU2007109812/04A patent/RU2403257C2/ru not_active IP Right Cessation
- 2005-08-18 MY MYPI20053879A patent/MY139831A/en unknown
- 2005-08-18 DE DE602005021889T patent/DE602005021889D1/de not_active Expired - Lifetime
- 2005-08-18 ES ES05826812T patent/ES2347166T3/es not_active Expired - Lifetime
- 2005-08-19 TW TW094128282A patent/TWI372149B/zh not_active IP Right Cessation
- 2005-08-19 UY UY29077A patent/UY29077A1/es not_active Application Discontinuation
- 2005-08-19 PA PA20058642801A patent/PA8642801A1/es unknown
-
2007
- 2007-02-04 IL IL181158A patent/IL181158A0/en unknown
- 2007-02-13 US US11/674,349 patent/US7393867B2/en not_active Expired - Lifetime
-
2008
- 2008-05-22 US US12/125,450 patent/US7652046B2/en not_active Expired - Lifetime
-
2010
- 2010-09-09 CY CY20101100823T patent/CY1110775T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6555328B1 (en) * | 1999-06-08 | 2003-04-29 | Aventis Pharmaceuticals Inc. | Screening methods for altering circadian rhythms and for human casein kinase I δ and/or ε phosphorylation of human clock proteins, period 1, -2 and -3 |
Non-Patent Citations (2)
| Title |
|---|
| Circadian regulation of GABA-A receptor functionbyCKI-epsilon-CKI-delta in the rat suprachiasmatic nuclei. Ning,K.,et al.Nature Neuroscience,Vol.7 No.5. 2004 * |
| Crystal Structure of a Conformation-Selective Casein Kinase-1Inhibitor. Mashhoon,N.,et al.J. Biol. Chem.,Vol.275 No.26. 2000 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100439367C (zh) | 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物 | |
| US7393867B2 (en) | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase I | |
| JP6352571B1 (ja) | キナーゼ阻害剤としての複素環式アミド | |
| US8637510B2 (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
| US7968536B2 (en) | Heterocyclic compounds useful as RAF kinase inhibitors | |
| ES2365258T3 (es) | Derivados de tiazol condensados como inhibidores de quinasa. | |
| EP1948652B1 (en) | Glucokinase activators | |
| US20110118236A1 (en) | Heterocyclic compound | |
| MXPA01011441A (es) | Derivados de 4,5,6,7-tetrahidroindazol como agentes antitumorales. | |
| CN112979631A (zh) | Parg抑制化合物 | |
| US9029545B2 (en) | Thienopyridine NOX2 inhibitors | |
| WO1997003986A1 (en) | Fused triazole compounds | |
| JP4931814B2 (ja) | カゼインキナーゼIεの阻害剤としての3−アリールチオインドール−2−カルボキサミド誘導体及びその類似体 | |
| TWI357897B (en) | 3-substituted-5- and 6-aminoalkyl indole-2-carboxy | |
| HK1105198B (en) | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1105198 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1105198 Country of ref document: HK |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20161013 Address after: Delaware Patentee after: Aventis Saab limited liability company Address before: new jersey Patentee before: Aventis Pharmaceuticals, Inc. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091125 Termination date: 20170818 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |